Skip to search formSkip to main contentSkip to account menu

heptaplatin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
The intermolecular forces between anti–cancer molecules such as Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplation… 
2015
2015
In the present study, the cytogenetic effects of the platinum based anti-tumour drug heptaplatin were analysed by measuring… 
2014
2014
PURPOSE Lobaplatin, heptaplatin, and dicycloplatin are three new platinum drugs. The aim of this study is to investigate the… 
2013
2013
Hybrid QM/MM calculations on adducts of five platinum-based anti-cancer drugs, namely cisplatin, oxaliplatin, lobaplatin, and… 
2011
2011
A novel water-soluble heptaplatin analogue, cis-[(4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3-dioxolane](3-hydroxy-1,1… 
2010
2010
The present study was conducted to test the possible teratogenic and toxic effects of anti-cancer drug heptaplatin (SKI 2053) on… 
2006
2006
Heptaplatin, a new platinum derivative, has several contradicting reports on the nephrotoxicity. Therefore, the aim of this study… 
2005
2005
5550 Background: Heptaplatin (SKI-2053R, Sunpla) is a platinum compound, which has shown equivalent anti-tumor activity and less… 
2004
2004
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single… 
2003
2003
PURPOSE Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been…